Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evenamide as Add-on in Treatment-resistant Schizophrenia
NCT07184619Phase 3Recruiting
- Sponsor
- Newron Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of evenamide in schizophrenia, sponsored by Newron Pharmaceuticals. Started Jan 2026; status: recruiting.
02
Drugs
evenamide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07184619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184619.